To Install, click here.
- Levulan® Kerastick®
(aminolevulinic acid HCl)
for Topical Solution, 20%
Levulan® Kerastick®Levulan® Kerastick® plus blue light illumination using the BLU-U® blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses (Grade 1 or 2) of the face or scalp.
Learn More >> - BLU-U®
Blue Light Photodynamic TherapyIlluminator
Model 4170
BLU-U®The BLU-U is a unique blue light that can kill the P. acnes bacteria in your skin.
Learn More >> - ClindaReach®
(Clindamycin Phosphate Topical Solution USP, 1%)
Pledgets
ClindaReach®ClindaReach is indicated for the topical treatment of acne vulgaris and is only available by prescription.
Learn More >>
News
DUSA Pharmaceuticals to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference on March 16 at 3:00 p.m. Eastern Time. |
August 6, 2010
DUSA Pharmaceuticals Receives Response from FDA on Orphan Drug Designation Status
August 3, 2010
DUSA Pharmaceuticals Reports Second Quarter 2010 Corporate Highlights and Financial Results
August 3, 2010 Conference Call
DUSA Pharmaceuticals Reports Second Quarter 2010 Corporate Highlights and Financial Results
Welcome
DUSA Pharmaceuticals, Inc.® is an integrated dermatology pharmaceutical company committed to improving people's health and confidence through its quality dermatological treatments. DUSA markets and continues to develop its Levulan® Photodynamic Therapy (PDT) technology platform, which is a treatment for the pre-cancerous skin lesions known as Actinic Keratoses (AK). DUSA is also developing certain internal indications of Levulan PDT.
DUSA's portfolio of complementary dermatology products includes ClindaReach®, which was acquired from Sirius Laboratories, Inc. ClindaReach is a topical acne treatment which includes a novel applicator for those hard-to-reach areas.
